BLTE vs. MLYS, ACRS, TYRA, TERN, TSVT, MCRB, HROW, EWTX, GNLX, and BTAI
Should you be buying Belite Bio stock or one of its competitors? The main competitors of Belite Bio include Mineralys Therapeutics (MLYS), Aclaris Therapeutics (ACRS), Tyra Biosciences (TYRA), Terns Pharmaceuticals (TERN), 2seventy bio (TSVT), Seres Therapeutics (MCRB), Harrow Health (HROW), Edgewise Therapeutics (EWTX), Genelux (GNLX), and BioXcel Therapeutics (BTAI). These companies are all part of the "pharmaceutical preparations" industry.
Belite Bio vs.
Mineralys Therapeutics (NASDAQ:MLYS) and Belite Bio (NASDAQ:BLTE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, community ranking, media sentiment, profitability, risk, dividends, earnings and institutional ownership.
Mineralys Therapeutics currently has a consensus price target of $36.20, suggesting a potential upside of 144.26%. Belite Bio has a consensus price target of $56.00, suggesting a potential upside of 272.59%. Given Belite Bio's higher probable upside, analysts plainly believe Belite Bio is more favorable than Mineralys Therapeutics.
Mineralys Therapeutics received 1 more outperform votes than Belite Bio when rated by MarketBeat users. Likewise, 100.00% of users gave Mineralys Therapeutics an outperform vote while only 85.71% of users gave Belite Bio an outperform vote.
0.5% of Belite Bio shares are held by institutional investors. 13.3% of Belite Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Belite Bio had 12 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 13 mentions for Belite Bio and 1 mentions for Mineralys Therapeutics. Belite Bio's average media sentiment score of 0.32 beat Mineralys Therapeutics' score of 0.00 indicating that Belite Bio is being referred to more favorably in the news media.
Summary
Belite Bio beats Mineralys Therapeutics on 6 of the 9 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BLTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Belite Bio Competitors List
Related Companies and Tools